Oral SERDs In Focus: EMERALD Findings and Practical Considerations for Evidence-Based Treatment Selection

EP: 1.When Stable Disease Progresses: ESR1 Mutations at the Point Of Progression In Juliana’s Case

EP: 2.Targeting Resistance: Liquid Biopsy and the Role of SERDs In ESR1-Mutated mBC

Now Viewing

EP: 3.Oral SERDs In Focus: EMERALD Findings and Practical Considerations for Evidence-Based Treatment Selection

EP: 4.Safety Profile and Patient Guidance for Elacestrant: Practical Considerations With Oral Elacestrant

EP: 5.From Trial to Practice: Real-World Outcomes and The Evolving SERD Landscape

EP: 6.Optimizing Multidisciplinary Care for ESR1-Mutated Breast Cancer: Strategies and Future Directions

Video content above is prompted by the following:

The discussion centers on the EMERALD trial, a significant phase 3 study examining the use of oral selective estrogen receptor degrader (SERD) elacestrant in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The trial compared elacestrant with standard endocrine therapies, demonstrating a significant improvement in progression-free survival, particularly in patients with ESR1 mutations. This breakthrough provides clinicians with a promising new treatment option for patients developing resistance to traditional therapies.

Post-trial analyses revealed additional insights, particularly regarding patient subgroups. The researchers found that patients who had been on first-line CDK 4/6 inhibitors for longer than a year showed an even more profound improvement in progression-free survival when treated withelacestrant. This subgroup analysis helps clinicians identify optimal candidates for the new therapy, providing a more personalized approach to metastatic breast cancer treatment.

The panelists discuss the implications of these findings for clinical practice, emphasizing the importance of molecular profiling and individualized treatment strategies. They highlight how the trial data support using elacestrant as a targeted therapy for patients with ESR1 mutations, particularly those who have demonstrated longer responses to initial CDK 4/6 inhibitor treatments. This approach represents a significant advancement in precision medicine, allowing for more tailored and potentially more effective treatment options for patients with metastatic breast cancer.